Glenmark Pharmaceuticals Limited (NSE: GLENMARK) is a global research-driven pharmaceutical company that develops and markets innovative drugs for major therapeutic areas such as dermatology, respiratory, oncology, and diabetes. The company operates in over 80 countries and has manufacturing facilities in India, Switzerland, and Argentina. The company’s revenue is primarily generated through the sale of branded formulations, APIs, and generics. Glenmark has a wide customer base, which includes leading pharmaceutical companies, healthcare providers, and distributors.
For the quarter ended December 31, 2022, Glenmark Pharmaceuticals reported a consolidated revenue of ₹2,161.47 crore, representing a YoY growth of 6%. The company’s net profit for the quarter was ₹430.5 crore, representing a YoY decline of 21% from ₹548.51 Crore. The company’s India business reported a revenue of ₹1,074.5 crore for the quarter, representing a YoY growth of 6.7%. The company’s North America business reported a revenue of ₹837.3 crore for the quarter, representing a year on year growth of 10.6%.